Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Riding High, Amylin Adding $465M Via Public Stock Sale

March 31, 2006

By Jennifer Boggs

Clinical Data Begins Pivotal Study Of Depression Drug

March 31, 2006

By Jennifer Boggs

Arteriocyte’s Focus: Stem Cells For Ischemic Repair

March 30, 2006

By Jennifer Boggs

Arteriocyte’s Focus: Stem Cells For Ischemic Repair

March 30, 2006

By Jennifer Boggs

Sequenom’s $30M In Private Money For Genetic Analysis

March 29, 2006

By Jennifer Boggs

Biotech Pipelines Sitting ‘Unexploited’ In Australia

March 29, 2006

By Jennifer Boggs

Biotech Pipelines Sitting Unexploited’ In Australia

March 29, 2006

By Jennifer Boggs

Sequenom’s $30M In Private Money For Genetic Analysis

March 29, 2006

By Jennifer Boggs

Systemic RNAi Data Leads To Alnylam Partnership With INEX

March 28, 2006

By Jennifer Boggs

Systemic RNAi Data Leads To Alnylam Partnership With INEX

March 28, 2006

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...